PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bevacizumab
/ administration & dosage
Biosimilar Pharmaceuticals
/ adverse effects
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Double-Blind Method
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Paclitaxel
/ administration & dosage
Treatment Outcome
Young Adult
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
pubmed:
25
7
2019
medline:
18
2
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin In this double-blind, parallel-group study, we recruited patients from 159 centers in 27 countries. Participants were randomized 1:1 to receive PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin on day 1 of each 21-day cycle for 4-6 cycles, followed by blinded monotherapy with PF-06439535 or bevacizumab-EU until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study. Randomization was stratified by region, sex, and smoking history. The primary endpoint was objective response rate (ORR) in accordance with RECIST 1.1, based on responses achieved by week 19 and confirmed by week 25. Between 21 May 2015 and 14 November 2016, 719 patients were randomized to the PF-06439535 group (n = 358) or the bevacizumab-EU group (n = 361). As of data cutoff for analysis of the primary endpoint (8 May 2017), 45.3% (95% confidence interval [CI] 40.01-50.57) of patients in the PF-06439535 group and 44.6% (95% CI 39.40-49.89) of patients in the bevacizumab-EU group achieved an objective response by week 19 that was confirmed by week 25. The unstratified ORR risk ratio was 1.015 (95% CI 0.863-1.193; 90% CI 0.886-1.163), and the unstratified ORR risk difference was 0.653% (95% CI - 6.608 to 7.908); all three CIs fell within pre-specified equivalence margins. Using final data after study completion (22 December 2017), no notable differences in progression-free survival or overall survival were observed between the groups. The most frequently reported grade 3 or higher treatment-emergent adverse events were hypertension, neutropenia, and anemia. There were no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity across treatment groups. Among patients with advanced non-squamous NSCLC, PF-06439535 demonstrated similarity to bevacizumab-EU in terms of efficacy. Safety profiles for the two treatments were comparable. ClinicalTrials.gov, NCT02364999. Pfizer.
Sections du résumé
BACKGROUND
BACKGROUND
PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin
METHODS
METHODS
In this double-blind, parallel-group study, we recruited patients from 159 centers in 27 countries. Participants were randomized 1:1 to receive PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin on day 1 of each 21-day cycle for 4-6 cycles, followed by blinded monotherapy with PF-06439535 or bevacizumab-EU until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study. Randomization was stratified by region, sex, and smoking history. The primary endpoint was objective response rate (ORR) in accordance with RECIST 1.1, based on responses achieved by week 19 and confirmed by week 25.
RESULTS
RESULTS
Between 21 May 2015 and 14 November 2016, 719 patients were randomized to the PF-06439535 group (n = 358) or the bevacizumab-EU group (n = 361). As of data cutoff for analysis of the primary endpoint (8 May 2017), 45.3% (95% confidence interval [CI] 40.01-50.57) of patients in the PF-06439535 group and 44.6% (95% CI 39.40-49.89) of patients in the bevacizumab-EU group achieved an objective response by week 19 that was confirmed by week 25. The unstratified ORR risk ratio was 1.015 (95% CI 0.863-1.193; 90% CI 0.886-1.163), and the unstratified ORR risk difference was 0.653% (95% CI - 6.608 to 7.908); all three CIs fell within pre-specified equivalence margins. Using final data after study completion (22 December 2017), no notable differences in progression-free survival or overall survival were observed between the groups. The most frequently reported grade 3 or higher treatment-emergent adverse events were hypertension, neutropenia, and anemia. There were no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity across treatment groups.
CONCLUSION
CONCLUSIONS
Among patients with advanced non-squamous NSCLC, PF-06439535 demonstrated similarity to bevacizumab-EU in terms of efficacy. Safety profiles for the two treatments were comparable.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov, NCT02364999.
FUNDING
BACKGROUND
Pfizer.
Identifiants
pubmed: 31338773
doi: 10.1007/s40259-019-00363-4
pii: 10.1007/s40259-019-00363-4
pmc: PMC6790355
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Banques de données
ClinicalTrials.gov
['NCT02364999']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-570Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Stat Med. 1985 Apr-Jun;4(2):213-26
pubmed: 4023479
JAMA. 2017 Jan 3;317(1):37-47
pubmed: 27918780
Regul Toxicol Pharmacol. 2018 Jun;95:236-243
pubmed: 29574193
Oncologist. 2004;9 Suppl 1:2-10
pubmed: 15178810
ESMO Open. 2017 Jan 16;1(6):e000142
pubmed: 28848668
J Clin Oncol. 2004 Jun 1;22(11):2184-91
pubmed: 15169807
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Lancet Haematol. 2018 Nov;5(11):e543-e553
pubmed: 30389036
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
J Clin Oncol. 2002 Nov 1;20(21):4368-80
pubmed: 12409337
Lung Cancer. 2012 Jun;76(3):362-7
pubmed: 22244743
J Clin Oncol. 2004 May 1;22(9):1589-97
pubmed: 15117980
Pharmaceuticals (Basel). 2017 Jan 28;10(1):
pubmed: 28134851
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Cancer Chemother Pharmacol. 2016 Apr;77(4):839-46
pubmed: 26984210
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Lancet Haematol. 2017 Aug;4(8):e350-e361
pubmed: 28712941
Target Oncol. 2017 Oct;12(5):599-610
pubmed: 28801849
Lancet Oncol. 2001 Nov;2(11):667-73
pubmed: 11902537
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Lancet Oncol. 2018 Jul;19(7):987-998
pubmed: 29880292
Clin Cancer Res. 2019 Apr 1;25(7):2088-2095
pubmed: 30617139
J Clin Oncol. 2018 Apr 20;36(12):1260-1265
pubmed: 29443651
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet Oncol. 2017 Jul;18(7):917-928
pubmed: 28592386
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029